Celecoxib Add-On Therapy Compared to Haloperidol Alone in Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT138809201457N6

Enrollment

Registered

2010-11-02

Start date

2004-03-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Haloperidoloral, 15-30 mg/day, orally, plus Celecoxib, 400 mg/day for 5 weeks. Intervention 2: Haloperidoloral, 15-30 mg/day, orally, plus placebo for 5 weeks.

Treatment - Drugs

Haloperidoloral, 15-30 mg/day, orally, plus Celecoxib, 400 mg/day for 5 weeks

Haloperidoloral, 15-30 mg/day, orally, plus placebo for 5 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: DSM-IV-TR criteria for schizophrenia, Information consent of patients and their tutor Exclusion criteria: Infectious diseases, inflammatory diseases, Anti-inflammatory drug consumption Inflammatory

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Schizophrenia symptoms. Timepoint: weekly. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Zarghami

Mazandaran University of Medical Sciences

mzarghami@mazums.ac.ir & mehran.zarghami@gmail.com+98 15 1328 5659

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026